

Marianne Martinello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2128469/publications.pdf>

Version: 2024-02-01

67
papers

1,606
citations

304368

22
h-index

329751

37
g-index

69
all docs

69
docs citations

69
times ranked

1976
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 133-143.	4.6	147
2	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. <i>Journal of Hepatology</i> , 2020, 72, 643-657.	1.8	103
3	Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay. <i>Journal of Infectious Diseases</i> , 2018, 217, 1889-1896.	1.9	88
4	Hepatitis C treatment as prevention: evidence, feasibility, and challenges. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 317-327.	3.7	80
5	<scp>HCV</scp> reinfection incidence among individuals treated for recent infection. <i>Journal of Viral Hepatitis</i> , 2017, 24, 359-370.	1.0	68
6	Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia. <i>Journal of Viral Hepatitis</i> , 2018, 25, 640-648.	1.0	68
7	Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. <i>Cell Reports Medicine</i> , 2021, 2, 100228.	3.3	66
8	Management of acute HCV infection in the era of direct-acting antiviral therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 412-424.	8.2	62
9	Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. <i>International Journal of Drug Policy</i> , 2018, 61, 23-30.	1.6	57
10	Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE II study. <i>Hepatology</i> , 2016, 64, 1911-1921.	3.6	50
11	HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs. <i>Current HIV/AIDS Reports</i> , 2017, 14, 110-121.	1.1	46
12	Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 1502-1510.	2.9	46
13	Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e69-e78.	2.9	43
14	Global elimination of hepatitis C virus by 2030: why not?. <i>Nature Medicine</i> , 2020, 26, 157-160.	15.2	42
15	Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study. <i>Journal of Viral Hepatitis</i> , 2020, 27, 281-293.	1.0	39
16	“We are what we eat!” Invasive intestinal mucormycosis: A case report and review of the literature. <i>Medical Mycology Case Reports</i> , 2012, 1, 52-55.	0.7	31
17	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , 2020, 72, 431-440.	1.8	30
18	Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. <i>Cell Reports</i> , 2022, 38, 110345.	2.9	30

#	ARTICLE	IF	CITATIONS
19	Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 371-393.	1.9	27
20	Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. <i>Journal of Hepatology</i> , 2021, 75, 829-839.	1.8	27
21	Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1180-1188.	1.0	25
22	Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 969-979.	1.0	25
23	Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection. <i>Hepatology</i> , 2020, 72, 7-18.	3.6	24
24	Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression. <i>Lancet HIV</i> , 2022, 9, e414-e427.	2.1	23
25	Prevalence and Disease Burden of HCV Coinfection in HIV Cohorts in the Asia Pacific Region: A Systematic Review and Meta-Analysis. <i>AIDS Reviews</i> , 2016, 18, 68-80.	0.5	21
26	Optimizing the detection of methicillin-resistant <i>Staphylococcus aureus</i> with elevated vancomycin minimum inhibitory concentrations within the susceptible range. <i>Infection and Drug Resistance</i> , 2016, 9, 87.	1.1	18
27	What do infectious diseases physicians do? A 2-week snapshot of inpatient consultative activities across Australia, New Zealand and Singapore. <i>Clinical Microbiology and Infection</i> , 2014, 20, O737-O744.	2.8	17
28	Enhancing the detection and management of acute hepatitis C virus infection. <i>International Journal of Drug Policy</i> , 2015, 26, 899-910.	1.6	16
29	Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw105.	0.4	16
30	Transmission of hepatitis C virus in HIV-positive and PrEP-using MSM in England. <i>Journal of Viral Hepatitis</i> , 2020, 27, 721-730.	1.0	16
31	Time to Detection of Hepatitis C Virus Infection With the Xpert HCV Viral Load Fingertick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis. <i>Journal of Infectious Diseases</i> , 2020, 221, 2043-2049.	1.9	16
32	Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort. <i>International Journal of Drug Policy</i> , 2021, 96, 103422.	1.6	15
33	Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. <i>International Journal of Drug Policy</i> , 2022, 105, 103706.	1.6	14
34	Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV. <i>Aids</i> , 2020, 34, 1347-1358.	1.0	12
35	Progress Toward Hepatitis C Virus Elimination. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 253-277.	1.0	11
36	Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The STOp-C Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 1809-1819.	2.9	11

#	ARTICLE	IF	CITATIONS
37	Buruli Ulcer Disease in Travelers and Differentiation of <i>Mycobacterium ulcerans</i> Strains from Northern Australia. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3717-3721.	1.8	10
38	Editorial: Observations on the launch of new drugs for hepatitis C. <i>Australian Prescriber</i> , 2018, 41, 4-5.	0.5	10
39	High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH Study. <i>Hepatology Communications</i> , 2022, 6, 496-512.	2.0	10
40	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. <i>JHEP Reports</i> , 2022, 4, 100462.	2.6	10
41	Hepatitis C elimination in Australia: progress and challenges. <i>Medical Journal of Australia</i> , 2020, 212, 362-363.	0.8	9
42	Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 2037-2044.	2.9	9
43	The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments. <i>Journal of Hepatology</i> , 2017, 66, S291-S292.	1.8	8
44	Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program. <i>Medical Journal of Australia</i> , 2021, 215, 332-333.	0.8	8
45	Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: a retrospective cohort study. <i>Sexual Health</i> , 2020, 17, 223.	0.4	8
46	Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: The REACH cohort. <i>Journal of Viral Hepatitis</i> , 2022, 29, 661-676.	1.0	7
47	A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study. <i>Viruses</i> , 2022, 14, 1555.	1.5	7
48	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. <i>Antiviral Therapy</i> , 2016, 21, 425-434.	0.6	6
49	A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015. <i>Journal of the International AIDS Society</i> , 2019, 22, e25222.	1.2	6
50	A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections. <i>Infection, Genetics and Evolution</i> , 2019, 69, 76-84.	1.0	6
51	Modeling based response guided therapy in subjects with recent hepatitis C infection. <i>Antiviral Research</i> , 2020, 180, 104862.	1.9	6
52	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. <i>Antiviral Therapy</i> , 2016, 21, 465-465.	0.6	5
53	<i>Editorial Commentary</i> : Interferon-free Hepatitis C Treatment Efficacy From Clinical Trials Will Translate to "Real World" Outcomes. <i>Clinical Infectious Diseases</i> , 2016, 62, 927-928.	2.9	5
54	Management of acute HCV in the era of direct-acting antivirals: implications for elimination. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 256-257.	3.7	5

#	ARTICLE	IF	CITATIONS
55	DAA treatment scale-up in HIV/HCV co-infection: characterising a population at risk for reinfection. <i>Journal of Hepatology</i> , 2017, 66, S495-S496.	1.8	4
56	Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia. <i>Journal of Hepatology</i> , 2018, 68, S312-S313.	1.8	4
57	THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection. <i>Journal of Hepatology</i> , 2019, 70, e231.	1.8	4
58	Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO): An open-label, single-arm, phase 4, multicentre trial. <i>Health Science Reports</i> , 2020, 3, e151.	0.6	4
59	Persistent high-level shedding of cultivable SARS-CoV-2 Delta virus 33 days after onset of COVID-19 in a hospitalized patient with pneumonia. <i>Journal of Medical Virology</i> , 2022, 94, 4043-4046.	2.5	4
60	The Impact of Ribavirin Plasma Concentration on the Efficacy of the Interferon-Sparing Regimen, Sofosbuvir and Ribavirin. <i>Antiviral Therapy</i> , 2016, 21, 127-132.	0.6	3
61	Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 271-279.	1.0	3
62	Incidence of HCV Reinfection among Treated Individuals with Recently Acquired Infection. <i>Journal of Hepatology</i> , 2016, 64, S620-S621.	1.8	2
63	Direct-acting antivirals for acute HCV: how short can we go?. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 316-318.	3.7	2
64	SAT-235-Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia. <i>Journal of Hepatology</i> , 2019, 70, e734.	1.8	2
65	PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. <i>Journal of Hepatology</i> , 2019, 70, e110.	1.8	2
66	Cure and Control: What Will It Take to Eliminate HCV?. <i>Topics in Medicinal Chemistry</i> , 2019, , 447-490.	0.4	2
67	HCV Elimination in Australia. , 2021, , 213-227.		0